3 models fit Nutex Health Inc. Common Stock and they disagree: 1 of 3 land within 15% of the average. The price is below every model.
Two or more of our models back this value.
Large discount(i)Silver75
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionNutex Health Inc. Common Stock (NUTX)
Fair value (3 models)
$619
ACCE price target
$225
Rating
Undervalued
Horizon
12 months
Fair value published on 23 Oct 2026, 10:03 CEST; previously $597 since 21 Oct 2026, 11:06 CEST.
ACCE price target published on 12 Oct 2026, 00:00 CEST.
Rating published on 21 Oct 2026, 11:06 CEST.
Price used: $210 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
66.2% below
+195.5% to fair value
ACCE score
75
out of 100
Analysts
100% buy
5 covering
P/E
8.3x
forward 10.3x
1-year return
+78.7%
Dividend yield
0.00%
Nutex Health Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Nutex Health runs a network of outpatient hospitals and micro-hospitals across Texas and several other states, with the bulk of revenue coming from acute and elective procedures billed to commercial payers and Medicare Advantage plans. Its edge is a dense local footprint in its core Texas markets, which gives it referral density and pricing leverage that a national operator would struggle to replicate. The near-term story is a shift in mix toward higher-margin ambulatory and surgical volume, and the 57.8% operating margin against a 54.5% gross margin shows how much the recent cost structure is working in its favour. Revenue fell 13.6%, though, so the margins are being earned on a shrinking top line, and the question for a PM is whether that decline reflects deliberate pruning of unprofitable sites or a real loss of volume. The 8.0x trailing P/E and 64.6% ROE make the name cheap on earnings and the balance sheet deserves a look, but the absence of index membership and the zero forward P/E (no consensus estimate) mean this needs a deeper look at the revenue trajectory before anything else.
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
high
Revenue declining while earnings jump
Revenue fell 13.6% year over year and 2.6% quarter over quarter, yet earnings rose 95.9%. Margin gains from a shrinking top line are harder to sustain.
high
Heavy short interest
Short interest stands at 28.9% of ownership. That level signals strong bearish conviction and can amplify volatility in either direction.
moderate
Leverage and enterprise value stretch
Debt to equity is 1.07 and EV/EBITDA is 90.0. The stock trades 6.8% below the ACCE price target of $225.00 and 66.2% below the model fair value of $619.42, so the gap reflects skepticism, not just cheapness.
moderate
Score fell 10 points in 90 days
The ACCE score dropped from 81 to 71 over 90 days, with growth at 43 and value at 56. The deterioration is concentrated in the growth and valuation pillars.
AI research notes
AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Free cash flow over the last 12 months reached $246M, and the stock's free cash flow yield stands at 18.8%.
Net margin of 21.3% and return on equity of 64.6% show the business turns sales into profit very efficiently.
Latest quarterly earnings per share beat expectations by 82.1%, and all five covering analysts rate the stock Buy or Strong Buy.
Why it could disappoint
Revenue fell 13.6% year over year, sharply reversing a five-year average growth rate of 26.1% per year.
Return on invested capital is only 8.5%, and debt equals 1.07 times equity, so returns depend heavily on borrowing.
The diluted share count rose 32.5% last fiscal year, so each share now represents a smaller slice of the business.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where NUTX's valuation models land
Price
$209.59
Model fair value
$619
Model range
$426 to $705
Fair value $619
Price $210
The price is below the whole model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores